Edaravone combined with hyperbaric oxygen therapy in delayed encephalopathy after acute carbon monoxide poisoning: A meta-analysis
Siyao Zeng,Yue Li,Zhipeng Yao,Yunlong Li,Yang Cao,Lianghe Wen,Ming Li,Junbo Zheng,Hongliang Wang
DOI: https://doi.org/10.1016/j.jocn.2024.06.018
IF: 2.116
2024-08-01
Journal of Clinical Neuroscience
Abstract:Background The use of both edaravone (EDA) and hyperbaric oxygen therapy (HBOT) is increasingly prevalent in the treatment of delayed encephalopathy after carbon monoxide poisoning (DEACMP). This meta-analysis aims to evaluate the efficacy of using EDA and HBOT in combination with HBOT alone in the treatment of DEACMP. Methods We searched and included all randomized controlled trials (RCTs) published before November 6, 2023, from 12 Chinese and English databases and clinical trial centers in China and the United States. The main outcome indicator was the total effective rate. The secondary outcome indicators included the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), National Institutes of Health Stroke Scale (NIHSS), Barthel Index (BI), Hasegawa Dementia Scale (HDS), Fugl-Meyer Assessment (FMA), Superoxide Dismutase (SOD), and Malondialdehyde (MDA). Statistical measures utilized include risk ratios (RR), weighted mean difference (WMD), and 95 % confidence intervals (95 % CI). Results Thirty studies involving a combined total of 2075 participants were ultimately incorporated. It was observed that the combination of EDA with HBOT for the treatment of DEACMP demonstrated an improvement in the total effective rate (RR: 1.25; 95 % CI: 1.20–1.31; P < 0.01), MMSE (WMD: 3.67; 95 % CI: 2.59–4.76; P < 0.01), MoCA (WMD: 4.38; 95 % CI: 4.00–4.76; P < 0.01), BI (WMD: 10.94; 95 % CI: 5.23–16.66; P < 0.01), HDS (WMD: 6.80; 95 % CI: 4.05–9.55; P < 0.01), FMA (WMD: 8.91; 95 % CI: 7.22–10.60; P < 0.01), SOD (WMD: 18.45; 95 % CI: 16.93–19.98; P < 0.01); and a reduction in NIHSS (WMD: −4.12; 95 % CI: −4.93 to –3.30; P < 0.01) and MDA (WMD: −3.05; 95 % CI: −3.43 to –2.68; P < 0.01). Conclusion Low-quality evidence suggests that for DEACMP, compared to using HBOT alone, the combined use of EDA and HBOT may be associated with better cognition and activity of daily living. In the future, conducting more meticulously designed multicenter and large-sample RCTs to substantiate our conclusions is essential.
neurosciences,clinical neurology